The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered

Behav Pharmacol. 2001 Feb;12(1):1-11. doi: 10.1097/00008877-200102000-00001.


Growing attention has been directed towards the potential involvement of the dopamine D3 receptor (D3R) in modulating effects of psychomotor stimulants. BP 897 (N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-2-naphthylcarboxamide; aka BP 4.897 and DO897) is amongst the most selective partial agonists for the D3R receptor thus far reported. BP 897 was tested for its ability to support self-administration in rhesus monkeys (0.3-30 microg/kg) and for its ability to produce cocaine- and D-amphetamine-like discriminative stimulus effects in mice (0.01-17 mg/kg i.p.). BP 897 was not self-administered above vehicle and saline levels in any of the four monkeys tested, and produced less than 30% generalization from either the cocaine or D-amphetamine stimulus. When BP 897 was administered before administrations of cocaine or D-amphetamine, percent drug-lever selections were reduced. These results suggest that BP 897 has a profile of activity suitable for consideration as a potential treatment for cocaine dependency disorders.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cocaine / pharmacology*
  • Conditioning, Operant
  • Dextroamphetamine / pharmacology*
  • Discrimination, Psychological / drug effects*
  • Dopamine Agonists / pharmacology*
  • Dopamine Uptake Inhibitors / pharmacology*
  • Dose-Response Relationship, Drug
  • Generalization, Psychological
  • Macaca mulatta
  • Male
  • Piperazines / pharmacology*
  • Receptors, Dopamine D2 / agonists*
  • Receptors, Dopamine D3
  • Self Administration
  • Substance-Related Disorders / psychology*


  • Dopamine Agonists
  • Dopamine Uptake Inhibitors
  • Piperazines
  • Receptors, Dopamine D2
  • Receptors, Dopamine D3
  • BP 897
  • Cocaine
  • Dextroamphetamine